The promise of Medicare’s MolDx program to provide greater reimbursement consistency and to fully reflect the value of molecular diagnostics has yet to be fulfilled, laboratory representatives argued at a diagnostics summit last month.
The Molecular Diagnostic Services, or MolDx, process for assessing CPT codes for reimbursement of lab tests “is taking more time than it should,” and not all molecular diagnostic tests with...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?